Moreover, treatment with these inhibitors disrupts CRC cell adaptation to acidic stress by interfering with tumor acidity regulation, suggesting a novel acid-modulating role for anticancer drugs that target integrin, FAK, and STAT3. The gene discussed is PTK2; the disease is neoplasm.